Charity Cure Leukaemia has announced two world-first Acute Myeloid Leukaemia (AML) clinical trials that will target patients who can’t undergo chemotherapy.
Acute myeloid leukaemia (AML) is a type of blood cancer and can affect children of any age.
The EVOLVER trials are announced on World AML Awareness Day and come following ongoing investment in the Trials Acceleration Programme (TAP) network.
The TAP network is primarily funded by Cure Leukaemia’s Tour 21 event, which see’s a team of amateur riders ride all 21 stages of the Tour de France one week ahead of the professionals.
Paresh Vyas is Professor of Haematology at the University of Oxford.
Vyas said: “We are on the cusp of launching two EVOLVE trials in collaboration with HOVON, Dutch hematology trials group, targeting AML patients who cannot undergo chemotherapy – a group for whom treatment options remain limited.
“Additionally, a new intensive chemo trial will open later this year at five TAP Centres and expanding to further centres by the end of 2026.
This marks a major advancement in personalising care for AML patients across the spectrum of need.”
Through its ongoing funding of Cure Leukaemia Research Nurses at 15 TAP Centres across the UK, Cure Leukaemia aims to accelerate international collaboration and cutting-edge research to improve AML care in the future.
Professor Charlie Craddock CBE, said: “The funding of clinical trials is the engine room of progress for AML patients.
“Cure Leukaemia’s support of the TAP network ensures we can rapidly deliver innovative treatments to those who urgently need them.
“It’s this international collaboration that will transform outcomes for blood cancer patients across the globe.”
